Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05669950 · ClinicalTrials.gov registry record · Phase 1

A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

A Phase 1 study of Congenital Adrenal Hyperplasia, sponsored by H. Lundbeck A/S.

Recruiting
Registry status
Phase 1
Development phase
42
Enrollment target
17
Study locations

NCT05669950 is a Phase 1 study of Congenital Adrenal Hyperplasia that is actively recruiting participants, run by H. Lundbeck A/S. The registered enrollment target is 42 participants, below the 97-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (57% lower). The trial reports 17 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05669950, a Phase 1 study of Congenital Adrenal Hyperplasia, is actively recruiting participants, sponsored by H. Lundbeck A/S.

RECRUITING
Registry status
Phase 1
Development phase
42 participants
Enrollment target
17
Study locations

Study Summary

This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and tolerability of Lu AG13909, how Lu AG13909 behaves in the body, and how the body responds to Lu AG13909.

Conditions Studied

Congenital Adrenal Hyperplasia

Interventions

  • DRUG Lu AG13909

Study Locations (17)

Other

  • Rigshospitalet - Copenhagen
  • Chu Angers - Angers
  • CHU de Lille - Lille
  • GH Pitié-Salpêtrière - Paris
  • CHRU Strasbourg - Strasbourg
  • David Metreveli Medical Centre, Tbilisi - Tbilisi
  • Beaumont Hospital Royal College of Surgeons in Ireland (RCSI), Dublin - Dublin
  • Azienda Ospedaliero Universitaria di Bologna - Bologna
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma - Roma
  • Centrum Nowoczesnych Terapii, Dobry Lekarz - Dobry Lekarz
  • Sahlgrenska University Hospital - Gothenburg
  • Karolinska University Hospital - Stockholm
  • NIHR/Wellcome Trust Clinical Research Facility - Birmingham
  • Cambridge Clinical Research Centre - Cambridge
  • NIHR Clinical Research Facility - London
  • University College London Hospital - NIHR - London

Michigan

  • University Hospital-University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2022-12-19
Est. Completion 2027-12-31
Phase Phase 1

Sponsor

H. Lundbeck A/S

72 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05669950

The ClinicalTrials.gov registry entry for NCT05669950 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (57% lower). The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Lu AG13909 is the first listed.

NCT05669950 reports 17 study locations spanning 2 distinct geographic areas - top geographies include Other, Michigan.

Frequently Asked Questions

What is clinical trial NCT05669950 about?

NCT05669950 is a clinical study titled "A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia". This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and...

What is the current status of trial NCT05669950?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-12-19. Estimated completion is 2027-12-31.

What conditions does trial NCT05669950 study?

This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia.

What interventions are being tested in trial NCT05669950?

The interventions under investigation include: Lu AG13909 (DRUG).

Who is sponsoring clinical trial NCT05669950?

This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05669950 being conducted?

This trial has 17 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Congenital Adrenal Hyperplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Congenital Adrenal Hyperplasia

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.